Somewhat Positive News Coverage Somewhat Unlikely to Affect Tocagen (TOCA) Stock Price

Headlines about Tocagen (NASDAQ:TOCA) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tocagen earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.1263661629812 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

A number of brokerages have commented on TOCA. BidaskClub upgraded Tocagen from a “hold” rating to a “buy” rating in a research note on Saturday, March 17th. Zacks Investment Research upgraded Tocagen from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Wednesday, March 14th. Finally, ValuEngine upgraded Tocagen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $21.50.

How to Become a New Pot Stock Millionaire

Shares of TOCA stock traded up $0.24 during trading hours on Friday, hitting $12.64. The company’s stock had a trading volume of 99,454 shares, compared to its average volume of 112,310. Tocagen has a 12 month low of $8.60 and a 12 month high of $17.95. The firm has a market capitalization of $246.90 and a PE ratio of -2.21. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.05.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Tocagen (TOCA) Stock Price” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3296558/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-tocagen-toca-stock-price.html.

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Insider Buying and Selling by Quarter for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Whiting Petroleum  Sets New 52-Week High and Low at $40.47
Whiting Petroleum Sets New 52-Week High and Low at $40.47
SilverBow Resources  Reaches New 52-Week High and Low at $34.76
SilverBow Resources Reaches New 52-Week High and Low at $34.76
Financial Comparison: Service Co. International  versus Yelp
Financial Comparison: Service Co. International versus Yelp
Critical Contrast: Morgan Stanley  and Its Competitors
Critical Contrast: Morgan Stanley and Its Competitors
Barfresh Food Group  vs. Lamb Weston  Head to Head Survey
Barfresh Food Group vs. Lamb Weston Head to Head Survey
Royal Bank of Canada Increases American Express  Price Target to $86.00
Royal Bank of Canada Increases American Express Price Target to $86.00


© 2006-2018 Ticker Report. Google+.